The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 08, 2023

Filed:

Dec. 31, 2020
Applicant:

Transthera Sciences (Nanjing), Inc., Nanjing, CN;

Inventor:

Frank Wu, Nanjing, CN;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/14 (2006.01); A61P 35/02 (2006.01); A61P 35/00 (2006.01); A61K 31/551 (2006.01); C07D 487/04 (2006.01); C07D 491/08 (2006.01); C07D 519/00 (2006.01); A61K 45/06 (2006.01); A61K 31/5517 (2006.01);
U.S. Cl.
CPC ...
C07D 471/14 (2013.01); A61K 31/551 (2013.01); A61K 31/5517 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07D 487/04 (2013.01); C07D 491/08 (2013.01); C07D 519/00 (2013.01);
Abstract

The present invention relates to a method for treating a cancer mediated by abnormality of multi-kinases, comprising administrating a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R, R, X, Y, P, W, and Ar are as defined in the description. Also provided is a method for treating a cancer mediated by abnormality of multi-kinases, comprising administrating a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-]pyrido[4,3-][1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4±0.2°, 17.9±0.2°, 18.9±0.2°, 19.4±0.2°, 21.5±0.2°, and 23.7±0.2°.


Find Patent Forward Citations

Loading…